TNF and metabolic dysfunction-associated steatotic liver disease: Interactions between immune function pathways and those describing the pathophysiology of chronic diseases such as type II diabetes mellitus and nonalcoholic fatty liver disease are likely to be similarly impacted by the observed reduction of certain inflammatory mediators (e. g., TNF-α) in RIS-treated mice.